This article is more than 5 years old. Information may no longer be current.
Aerie to manufacture Rhopressa, Roclatan in Ireland
Aerie Pharmaceuticals plans to commercially produce its product candidates Rhopressa and Roclatan in Ireland following the signing of a lease agreement with Ireland’s Industrial Development Agency, the company announced in a press release.
Aerie will begin work on the interior of the already built 30,000-square-foot building shell in Athlone, Ireland, immediately. The project is expected to cost about $25 million, the release said.
If Rhopressa (netarsudil ophthalmic solution 0.02%) is approved, it is expected to be available from the new plant by 2020. Roclatan (netarsudil 0.02%/latanoprost ophthalmic solution 0.005%) is currently undergoing two phase 3 trials. If the trials are successful, Aerie expects to file its new drug application by the end of the year, according to the release.